|
1
|
Martz N, Benziane-Ouaritini N, Gautier M,
Brenot-Rossi I, Montagne L, Salem N, Bodokh Y and Hannoun-Levi JM:
Brachytherapy for oligometastatic prostate cancer to the penis. J
Contemp Brachytherapy. 13:593–597. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Fiaschetti V, Liberto V, Claroni G, Loreni
G, Formica V, Roselli M, Mauriello A and Floris R: Relevance of
computed tomography and magnetic resonance imaging for penile
metastasis after prostatectomy: uncommon case report and brief
review of the literature. Radiol Case Rep. 11:255–259. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang Z, Xu M, Shang M, Liu Z, Yang L and
Yu D: Case report: Malignant priapism: Penile metastasis from
prostate cancer with low serum PSA level. Front Oncol.
14:13953012025. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu YM, Cieślik M, Lonigro RJ, Vats P,
Reimers MA, Cao X, Ning Y, Wang L, Kunju LP, de Sarkar N, et al:
Inactivation of CDK12 delineates a distinct immunogenic class of
advanced prostate cancer. Cell. 173:1770–1782.e14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jiang C, Hong Z, Liu S, Hong Z and Dai B:
Roles of CDK12 mutations in PCa development and treatment. Biochim
Biophys Acta Rev Cancer. 1880:1892472025. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Amin MB, Greene FL, Edge SB, Compton CC,
Gershenwald JE, Brookland RK, Meyer L, Gress DM, Byrd DR and
Winchester DP: The eighth edition AJCC cancer staging manual:
Continuing to build a bridge from a population-based to a more
‘personalized’ approach to cancer staging. CA Cancer J Clin.
67:93–99. 2017.PubMed/NCBI
|
|
7
|
Montironi R, Cheng L, Scarpelli M and
Lopez-Beltran A: Pathology and genetics: Tumours of the urinary
system and male genital system: clinical implications of the 4th
Edition of the WHO Classification and Beyond. Eur Urol. 70:120–123.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kamaleshwaran KK, Balasundararaj BKP, Jose
R and Shinto AS: Penile metastasis from prostate cancer presenting
as malignant priapism detected using gallium-68 prostate-specific
membrane antigen positron emission tomography/computed tomography.
Indian J Nucl Med. 33:57–58. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fujita N, Kurokawa R, Kaneshima R, Machida
M, Kawai G, Wada T, Takahashi M, Nakaya M, Sakamoto N, Cho S, et
al: Patient with penile metastasis from prostate cancer and
survival over 5 years: A case report with longitudinal evaluation
using computed tomography and magnetic resonance imaging. Radiol
Case Rep. 16:1255–1258. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cocci A, Hakenberg OW, Cai T, Nesi G, Livi
L, Detti B, Minervini A, Morelli G, Carini M, Serni S and Gacci M:
Prognosis of men with penile metastasis and malignant priapism: A
systematic review. Oncotarget. 9:2923–2930. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He D, Zeng J, Li X, Wu K, Wu D, He H, Song
W and Li L: Priapism as the initial manifestation of a penile and
lower limb cutaneous metastasis of prostate adenocarcinoma with low
serum PSA level. J Androl. 33:1160–1164. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cardoso Guimarães G, Rodrigues De Souza R,
Paiva Gadêlha Guimarães A, Filho WD, Valeschka De Matos Granja N,
Karan Kalil R, Augusto Soares F and Lopes A: Penile metastasis of
chondrosarcoma of the jaw. Urology. 61:8372003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin YH, Kim JJ, Stein NB and Khera M:
Malignant Priapism Secondary to Metastatic Prostate Cancer: A case
report and review of literature. Rev Urol. 13:90–94.
2011.PubMed/NCBI
|
|
14
|
Dai Y, Shi BL, Zhang J, Liu SN and Jia YT:
Penile metastasis from prostate cancer misdiagnosed as Peyronie
disease: A case report. Sex Med. 11:qfac0112023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rocher L, Glas L, Cluzel G, Ifergan J and
Bellin MF: Imaging tumours of the penis. Diagn Interv Imaging.
93:319–328. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tatkovic A, McBean R, Schoeman J and Wong
D: Prostate penile metastasis: Incidence and imaging pattern on 68
Ga-PSMA PET/CT. J Med Imaging Radiat Oncol. 64:499–504. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dhull VS, Kshirsagar P, Chowhan M and
Patil SC: Solitary penile metastasis from prostate cancer on
18F-Prostate-specific membrane antigen positron emission
tomography/computed tomography. Indian J Nucl Med. 37:402–403.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Landen L, Devos G, Joniau S and Albersen
M: Penile metastasis in prostate cancer patients: Two case reports,
surgical excision technique, and literature review. Curr Urol.
17:165–172. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Atag E, Semiz HS, Kazaz SN, Tuna EB,
Ozdogan O, Bozkurt O, Demir O and Karaoglu A: Response to
cabazitaxel beyond 20 cycles in a patient with penile metastasis of
prostate cancer: A case report. Urol J. 14:2985–2988.
2017.PubMed/NCBI
|
|
20
|
Huggins C: Effect of orchiectomy and
irradiation on cancer of the prostate. Ann Surg. 115:1192–1200.
1942. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Armstrong AJ, Szmulewitz RZ, Petrylak DP,
Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi
T, Shore ND, et al: ARCHES: A Randomized, phase III study of
androgen deprivation therapy with enzalutamide or placebo in men
with metastatic hormone-sensitive prostate cancer. J Clin Oncol.
37:2974–2986. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davis ID, Martin AJ, Stockler MR, Begbie
S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath
LG, et al: Enzalutamide with standard first-line therapy in
metastatic prostate cancer. N Engl J Med. 381:121–131. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fong PC, Boss DS, Yap TA, Tutt A, Wu P,
Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, et
al: Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA
mutation carriers. N Engl J Med. 361:123–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Asim M, Tarish F, Zecchini HI, Sanjiv K,
Gelali E, Massie CE, Baridi A, Warren AY, Zhao W, Ogris C, et al:
Synthetic lethality between androgen receptor signalling and the
PARP pathway in prostate cancer. Nat Commun. 8:3742017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Saad F, Clarke NW, Oya M, Shore N,
Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, et al:
Olaparib plus abiraterone versus placebo plus abiraterone in
metastatic castration-resistant prostate cancer (PROpel): Final
prespecified overall survival results of a randomised,
double-blind, phase 3 trial. Lancet Oncol. 24:1094–1108. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chi KN, Sandhu S, Smith MR, Attard G, Saad
M, Olmos D, Castro E, Roubaud G, Pereira de Santana Gomes AJ, Small
EJ, et al: Niraparib plus abiraterone acetate with prednisone in
patients with metastatic castration-resistant prostate cancer and
homologous recombination repair gene alterations: Second interim
analysis of the randomized phase III MAGNITUDE trial. Ann Oncol.
34:772–782. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Agarwal N, Azad AA, Carles J, Fay AP,
Matsubara N, Heinrich D, Szczylik C, De Giorgi U, Young Joung J,
Fong PCC, et al: Talazoparib plus enzalutamide in men with
first-line metastatic castration-resistant prostate cancer
(TALAPRO-2): A randomised, placebo-controlled, phase 3 trial.
Lancet. 402:291–303. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mateo J, Carreira S, Sandhu S, Miranda S,
Mossop H, Perez-Lopez R, Nava Rodrigues D, Robinson D, Omlin A,
Tunariu N, et al: DNA-Repair defects and olaparib in metastatic
prostate cancer. N Engl J Med. 373:1697–1708. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Beer TM, Armstrong AJ, Rathkopf D, Loriot
Y, Sternberg CN, Higano CS, Iversen P, Evans CP, Kim CS, Kimura G,
et al: Enzalutamide in men with chemotherapy-naïve metastatic
castration-resistant prostate cancer: Extended analysis of the
phase 3 PREVAIL Study. Eur Urol. 71:151–154. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Greenleaf AL: Human CDK12 and CDK13,
multi-tasking CTD kinases for the new millenium. Transcription.
10:91–110. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhang W, Zhou L and Di J: Prognostic and
clinicopathological value of CDK12 mutation in prostate cancer: A
meta-analysis. Expert Rev Anticancer Ther. 23:207–216. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nguyen B, Mota JM, Nandakumar S, Stopsack
KH, Weg E, Rathkopf D, Morris MJ, Scher HI, Kantoff PW, Gopalan A,
et al: Pan-cancer analysis of CDK12 alterations identifies a subset
of prostate cancers with distinct genomic and clinical
characteristics. Eur Urol. 78:671–679. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong B, Fan L, Yang B, Chen W, Li Y, Wu K,
Zhang F, Dong H, Cheng H, Pan J, et al: Use of circulating tumor
DNA for the clinical management of metastatic castration-resistant
prostate cancer: A multicenter, real-world study. J Natl Compr Canc
Netw. 19:905–914. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Reimers MA, Yip SM, Zhang L, Cieslik M,
Dhawan M, Montgomery B, Wyatt AW, Chi KN, Small EJ, Chinnaiyan AM,
et al: Clinical outcomes in cyclin-dependent kinase 12 mutant
advanced prostate cancer. Eur Urol. 77:333–341. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schweizer MT, Ha G, Gulati R, Brown LC,
McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, et al:
CDK12-mutated prostate cancer: Clinical outcomes with standard
therapies and immune checkpoint blockade. JCO Precis Oncol.
4:382–392. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu S, Bao Y, Zheng L, Zhao J, Chen Y,
Huang R, Sun G, Zhao F, Zhang X, Liang J, et al: Chronological
liquid biopsy reveals the impact of platinum-based chemotherapy on
a prostate cancer patient's CDK12 mutation: A case report. Onco
Targets Ther. 15:947–952. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Barata P, Ledet E, Manogue C, Cotogno P,
Harris K, Lewis B, Layton J and Sartor O: Long-term disease control
using taxane/platinum-based chemotherapy in CDK12-mutated advanced
prostate cancer. Oncologist. 25:e1421–e1422. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Murata Y, Kosaka T, Nakamura K, Baba Y,
Arai E, Yasumizu Y, Matsumoto K, Nishihara H and Oya M: A case of
testicular dysgenesis syndrome with squamous cell carcinoma of the
prostate harboring a CDK12 mutation. IJU Case Rep. 8:125–128. 2025.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mota JM, Barnett E, Nauseef JT, Nguyen B,
Stopsack KH, Wibmer A, Flynn JR, Heller G, Danila DC, Rathkopf D,
et al: Platinum-based chemotherapy in metastatic prostate cancer
with DNA repair gene alterations. JCO Precis Oncol. 4:355–366.
2020. View Article : Google Scholar : PubMed/NCBI
|
